Showing results (311-320 of 446) with videos related to
Sort By:
Pageof 45
European Journal of Cancer (Oxford, England : 1990)|March 18, 2020
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.The Lancet. Oncology|April 2, 2026
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 studyShahneen Sandhu, Anthony M Joshua, Louise Emmett, et al.BMC Cancer|November 16, 2019
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinomaHannah L Buckley, Fiona J Collinson, Gemma Ainsworth, et al.European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapyViktor Grünwald, Pierre I Karakiewicz, Sevil E Bavbek, et al.The Journal of Pathology|October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomasMarco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.The Lancet. Oncology|February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trialReinhard Dummer, Jan C Brase, James Garrett, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced MelanomaCaroline Robert, Matteo S Carlino, Catriona McNeil, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic MelanomaYibing Yan, Matthew J Wongchenko, Caroline Robert, et al.Cancer Cell|April 28, 2023
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancerMary Y Wu, Scott T C Shepherd, Annika Fendler, et al.Cell Reports. Medicine|October 14, 2022
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerAnnika Fendler, Scott T C Shepherd, Lewis Au, et al.Pageof 45